Mini-Review

Comparison of CAR-T Cells Engineering using CD19 and CRISPR/Cas9

Monireh Bahrami

Monireh Bahrami
VarastehQazal Institute. Email: monireh.bahrami@yahoo.com
Online First: June 30, 2019 | Cite this Article
Bahrami, M. 2019. Comparison of CAR-T Cells Engineering using CD19 and CRISPR/Cas9. Journal of Genes and Cells 5(1): 1-6. DOI:10.15562/gnc.67


Cancer is the second largest cause of mortality in the world accounting more than 13% deaths. Currently, cancer is being treated by several hazardous approaches such as chemotherapy or radiotherapy and much attention has been seen in last decades on the development of novel targeted therapeutic approaches. Clinical data have suggested the engineering immunity as a one of the most promising approach in cancer treatment where engineering T cells has shown >99% efficiency to cure cancer. T-cells are being engineered for CD19 based chimeric antigen receptors by using lentiviral vectors and also for T-cell receptors using ribonucleoprotein based CRISPR/Cas9 gene editing tool. Activation of T-cells via engineering as immunotherapeutic cancer approach could create a new horizon of targeted therapeutic research in coming years and recent huge investment by global leading pharmaceutical companies in T-cell engineering have proven that a live cell-based drug in near future for cancer cure is not a myth anymore. 

No Supplementary Material available for this article.
Article Views      : 398
PDF Downloads : 104

Related Articles

Search Authors in












  • Monireh Bahrami

  • Monireh Bahrami

  • Monireh Bahrami